<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01117181</url>
  </required_header>
  <id_info>
    <org_study_id>R01AG033032-01</org_study_id>
    <secondary_id>R01AG033032-01</secondary_id>
    <nct_id>NCT01117181</nct_id>
  </id_info>
  <brief_title>Apathy in Dementia Methylphenidate Trial (ADMET)</brief_title>
  <acronym>ADMET</acronym>
  <official_title>Apathy in Dementia Methylphenidate Trial (ADMET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Apathy in Dementia Methylphenidate Trial (ADMET) is a masked, placebo-controlled trial
      that will examine the efficacy and safety of methylphenidate for the treatment of clinically
      significant apathy in patients with Alzheimer's dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Apathy in Dementia Methylphenidate Trial (ADMET), funded by the National Institute of
      Aging, is a Phase II, placebo-controlled, masked, 3-center randomized clinical trial. ADMET
      will enroll 60 patients with Alzheimer's disease (AD) and significant apathy from outpatient,
      nursing home, and assisted living facilities along with their primary caregiver. Eligible and
      willing patients will be randomly assigned to methylphenidate (20 mg per day) or placebo. At
      baseline and each in-person follow-up visit, all caregivers and patients will be provided
      with a standardized psychosocial intervention consisting of a counseling session, provision
      of educational materials, and 24-hour availability for crises. Efficacy and safety outcomes
      will be measured at baseline and at in-person follow-up visits at 2, 4, and 6 weeks following
      randomization. Telephone contact will take place at 1, 3, and 5 weeks after randomization.

      ADMET has 80% power to detect a difference of at least 3.3 in change in the Apathy Evaluation
      Scale scores between the two treatment groups. It also has 80% power to detect an absolute
      difference of 35% or more in the change in the proportion of study participants improving on
      te Clinical Global Impression of Change, given that 20% to 305 of participants in the placebo
      group show improvement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apathy Evaluation Scale (AES)</measure>
    <time_frame>baseline to 6 weeks</time_frame>
    <description>Change in score of Apathy Evaluation Scale from baseline to 6 weeks; the minimum score is 18; the maximum score is 72. Higher scores indicate more severe apathy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change</measure>
    <time_frame>baseline to 6 weeks</time_frame>
    <description>Proportion of individuals improving on Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (CGIC) from baseline to 6 weeks; the CGIC is a 7-point Likert scale used to rate each patient with the following scores: &quot;marked worsening&quot;(7), &quot;moderate worsening&quot; (6), &quot;minimal worsening&quot;(5), &quot;no change&quot;(4), &quot;minimal improvement&quot;(3), &quot;moderate improvement&quot;(2), &quot;marked improvement&quot;(1). Ratings were based on an interview with the caregiver and an examination of the patient. The CGIC requires the clinician to consider a number of aspects of apathy, such as level of initiative, level of interest, and emotional engagement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Digit Span</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>Change in Digit Span at baseline and 6 weeks; this assessment is used to assess auditory attention and working memory. Higher numbers indicate better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Exam (MMSE)</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>Change in Mini-Mental State Exam score from baseline to 6 weeks; this cognitive test estimates of dementia severity. Domains included orientation, memory, working memory, naming, following verbal and written commands, spontaneously writing a sentence, and copying two overlapping pentagons. The minimum MMSE score is 0; the maximum MMSE score is 30. Lower MMSE scores indicate more severe cognitive impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Inventory (NPI): Apathy Subscale</measure>
    <time_frame>baseline to week 6</time_frame>
    <description>Change from baseline to 6 weeks in neuropsychiatric symptoms in apathy subscore. Frequency (ranges from 1=occasionally, less than once/week to 4 = very frequently, once or more/day or continuously) and severity (1=mild, 2=moderate, 3=severe) scales are scored based on responses from an informed caregiver involved in the patient's life. To obtain the NPI score, the severity score is multiplied by the frequency score. Range is 0 to 12. Larger numbers indicate more severe behavioral disturbance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Status</measure>
    <time_frame>vital status at 6 weeks</time_frame>
    <description>vital status as measured by death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrolytes</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percent abnormal at 6 weeks as assessed by local lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Abnormal electrocardiogram results at 6 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Apathy</condition>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Methylphenidate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo and psychosocial intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>The target dose is 20 mg per day provided as two 10 mg doses administered orally. Patients will start by taking 10 mg daily (two 5 mg over-encapsulated tablets) for three days, at which time the dose will be increased to 20 mg per day (four 5 mg over-encapsulated tablets). In the event of significant side-effects, the dose will be reduced to a minimum of 10 mg per day. The study drug will be administered for 6 weeks.</description>
    <arm_group_label>Methylphenidate</arm_group_label>
    <other_name>Ritalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>dummy pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psychosocial intervention</intervention_name>
    <description>The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.
The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:
Review and adjustment of the patient and caregiver supportive care plans
Emotional support and opportunity to ventilate feelings
Counseling regarding specific caregiving skills
Assistance with problem solving of specific issues that the caregiver brings to the sessions
Answers for questions regarding the educational materials
The educational materials will consist of a copy of the book The 36-Hour Day</description>
    <arm_group_label>Methylphenidate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Possible or probable Alzheimer's disease (National Institute of Neurological and
             Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders
             Association (NINCDS-ADRDA) criteria), with Mini-Mental State Exam (MMSE) score of
             10-26 inclusive; MMSE scores above 26 in those who nevertheless meet criteria for AD
             may be allowed with Steering Committee approval on a case by case basis

          -  Clinically significant apathy for at least four weeks for which either 1) the
             frequency of apathy as assessed by the Neuropsychiatric Inventory (NPI) is 'Very
             frequently', or 2) the frequency of apathy as assessed by the NPI is 'Frequently' or
             'Often' AND the severity of apathy as assessed by the NPI is 'Moderate' or 'Marked'

          -  A medication for apathy is appropriate, in the opinion of the study physician

          -  Provision of informed consent for participation in the study by patient or surrogate
             (if the patient is unable to provide informed consent) and caregiver

          -  Availability of primary caregiver, who spends greater than ten hours a week with the
             patient and supervises his/her care, to accompany the patient to study visits and to
             participate in the study

          -  Sufficient fluency, of both the patient and caregiver, in written and spoken English
             to participate in study visits, physical exams, and outcome assessments

          -  No change to AD medications within the month preceding randomization, including
             starting, stopping, or dosage modifications

          -  Treatment with stable doses of selective serotonin reuptake inhibitor
             antidepressants(SSRIs) is appropriate if stable for 3 months prior to randomization.
             Other psychotropics(with the exclusion of antipsychotics), if stable for 3 months, may
             be allowed only with Steering Committee approval on a case by case basis.

        Exclusion criteria:

          -  Meets criteria for Major Depressive Episode, by Diagnostic Statistical Manual of
             Mental Disorder - IV (TR) criteria

          -  Clinically significant agitation /aggression for which either 1) the frequency of
             agitation /aggression as assessed by the NPI is 'Very frequently', or 2) the frequency
             of agitation /aggression as assessed by the NPI is 'Frequently' AND the severity of
             the agitation as assessed by the NPI is 'Moderate', or 'Marked'

          -  Clinically significant delusions for which either 1) the frequency of delusions as
             assessed by the NPI is 'Very frequently', or 2) the frequency of delusions as assessed
             by the NPI is 'Frequently' AND the severity of the delusions as assessed by the NPI is
             'Moderate', or 'Marked'

          -  Clinically significant hallucinations for which either 1) the frequency of
             hallucinations as assessed by the NPI is 'Very frequently', or 2) the frequency of
             hallucinations as assessed by the NPI is 'Frequently' AND the severity of the
             hallucinations as assessed by the NPI is 'Moderate', or 'Marked'

          -  Treatment with psychotropic medications in the 2 weeks prior to randomization with the
             exception of approved treatments for dementia (ChEIs and memantine), selective
             serotonin reuptake inhibitor antidepressants, and trazodone (if used as an aid to
             facilitate sleep and not as an antidepressant); other psychotropics (with the
             exclusion of antipsychotics), if stable for 3 months, may be allowed only with
             Steering Committee approval on a case by case basis. Note that antipsychotics are
             expressly prohibited.

          -  Treatment with methylphenidate is contraindicated in the opinion of the study
             physician

          -  Failure of treatment with methylphenidate in the past for apathy after convincing
             evidence of an adequate trial as judged by study physician

          -  Treatment with a medication that would prohibit the safe concurrent use of
             methylphenidate such as monoamine oxidase inhibitors and tricyclic antidepressants

          -  Need for acute psychiatric hospitalization or is suicidal

          -  Uncontrolled hypertension (medication non-compliance or past 3 months with a diastolic
             reading of 105 as verified by compartment pressure of the rectus sheath (CPRS))

          -  Symptomatic coronary artery disease deemed to be significant by study physician at the
             time of screening

          -  Lack of appetite that results in significant unintentional weight loss as determined
             by the study physician in the last three months

          -  Significant communicative impairments

          -  Current participation in a clinical trial or in any study that may add significant
             burden or affect study outcomes

          -  Hyperthyroidism, advanced arteriosclerosis, symptomatic cardiovascular disease,
             serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm
             abnormalities, or a family history of sudden death or death related to heart problems

          -  Glaucoma, pheochromocytoma, or known or suspected hypersensitivity to methylphenidate
             or its excipients

          -  Central Nervous System (CNS) abnormalities (e.g., cerebral aneurysm) and/or other
             vascular abnormalities such as vasculitis or pre-existing stroke, motor tics or a
             family history or diagnosis of Tourette's syndrome, seizures (convulsions, epilepsy),
             or abnormal EEGs

          -  Any condition that, in the opinion of the study physician, makes it medically
             inappropriate or risky for the patient to enroll in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberta Scherer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacobo Mintzer, MD, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Rosenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krista Lanctot, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.admet.org</url>
    <description>ADMET website</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2010</study_first_posted>
  <results_first_submitted>February 11, 2013</results_first_submitted>
  <results_first_submitted_qc>April 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 10, 2013</results_first_posted>
  <last_update_submitted>April 1, 2013</last_update_submitted>
  <last_update_submitted_qc>April 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Apathy</keyword>
  <keyword>Methylphenidate</keyword>
  <keyword>Dopaminergic agents</keyword>
  <keyword>Apathy Evaluation Scale</keyword>
  <keyword>Dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Clinical center recruited from established outpatient clinics, from living facilities, by local physicians, and from targeted advertisements in local media. The recruitment period started June 2010 and ended October 2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Methylphenidate</title>
          <description>Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>matching placebo and psychosocial intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Methylphenidate</title>
          <description>Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>matching placebo and psychosocial intervention</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78" spread="8"/>
                    <measurement group_id="B2" value="75" spread="9"/>
                    <measurement group_id="B3" value="76" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Apathy Evaluation Scale (AES)</title>
        <description>Change in score of Apathy Evaluation Scale from baseline to 6 weeks; the minimum score is 18; the maximum score is 72. Higher scores indicate more severe apathy.</description>
        <time_frame>baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylphenidate</title>
            <description>Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), and psychosocial intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo and psychosocial intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Apathy Evaluation Scale (AES)</title>
          <description>Change in score of Apathy Evaluation Scale from baseline to 6 weeks; the minimum score is 18; the maximum score is 72. Higher scores indicate more severe apathy.</description>
          <units>change in score on AES</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="1.5" lower_limit="-6.5" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.6" spread="1.4" lower_limit="-6.5" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change</title>
        <description>Proportion of individuals improving on Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (CGIC) from baseline to 6 weeks; the CGIC is a 7-point Likert scale used to rate each patient with the following scores: &quot;marked worsening&quot;(7), &quot;moderate worsening&quot; (6), &quot;minimal worsening&quot;(5), &quot;no change&quot;(4), &quot;minimal improvement&quot;(3), &quot;moderate improvement&quot;(2), &quot;marked improvement&quot;(1). Ratings were based on an interview with the caregiver and an examination of the patient. The CGIC requires the clinician to consider a number of aspects of apathy, such as level of initiative, level of interest, and emotional engagement.</description>
        <time_frame>baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylphenidate</title>
            <description>Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), and psychosocial intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo and psychosocial intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change</title>
          <description>Proportion of individuals improving on Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (CGIC) from baseline to 6 weeks; the CGIC is a 7-point Likert scale used to rate each patient with the following scores: &quot;marked worsening&quot;(7), &quot;moderate worsening&quot; (6), &quot;minimal worsening&quot;(5), &quot;no change&quot;(4), &quot;minimal improvement&quot;(3), &quot;moderate improvement&quot;(2), &quot;marked improvement&quot;(1). Ratings were based on an interview with the caregiver and an examination of the patient. The CGIC requires the clinician to consider a number of aspects of apathy, such as level of initiative, level of interest, and emotional engagement.</description>
          <units>% patients moderate/marked improvement</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Digit Span</title>
        <description>Change in Digit Span at baseline and 6 weeks; this assessment is used to assess auditory attention and working memory. Higher numbers indicate better functioning.</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <posting_date>08/2013</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mini-Mental State Exam (MMSE)</title>
        <description>Change in Mini-Mental State Exam score from baseline to 6 weeks; this cognitive test estimates of dementia severity. Domains included orientation, memory, working memory, naming, following verbal and written commands, spontaneously writing a sentence, and copying two overlapping pentagons. The minimum MMSE score is 0; the maximum MMSE score is 30. Lower MMSE scores indicate more severe cognitive impairment.</description>
        <time_frame>baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylphenidate</title>
            <description>Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), and psychosocial intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo and psychosocial intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Mini-Mental State Exam (MMSE)</title>
          <description>Change in Mini-Mental State Exam score from baseline to 6 weeks; this cognitive test estimates of dementia severity. Domains included orientation, memory, working memory, naming, following verbal and written commands, spontaneously writing a sentence, and copying two overlapping pentagons. The minimum MMSE score is 0; the maximum MMSE score is 30. Lower MMSE scores indicate more severe cognitive impairment.</description>
          <units>change in MMSE score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.6"/>
                    <measurement group_id="O2" value="-0.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychiatric Inventory (NPI): Apathy Subscale</title>
        <description>Change from baseline to 6 weeks in neuropsychiatric symptoms in apathy subscore. Frequency (ranges from 1=occasionally, less than once/week to 4 = very frequently, once or more/day or continuously) and severity (1=mild, 2=moderate, 3=severe) scales are scored based on responses from an informed caregiver involved in the patient's life. To obtain the NPI score, the severity score is multiplied by the frequency score. Range is 0 to 12. Larger numbers indicate more severe behavioral disturbance.</description>
        <time_frame>baseline to week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylphenidate</title>
            <description>Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo and psychosocial intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychiatric Inventory (NPI): Apathy Subscale</title>
          <description>Change from baseline to 6 weeks in neuropsychiatric symptoms in apathy subscore. Frequency (ranges from 1=occasionally, less than once/week to 4 = very frequently, once or more/day or continuously) and severity (1=mild, 2=moderate, 3=severe) scales are scored based on responses from an informed caregiver involved in the patient's life. To obtain the NPI score, the severity score is multiplied by the frequency score. Range is 0 to 12. Larger numbers indicate more severe behavioral disturbance.</description>
          <units>change in NPI apathy score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="0.6"/>
                    <measurement group_id="O2" value="-2.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Status</title>
        <description>vital status as measured by death</description>
        <time_frame>vital status at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylphenidate</title>
            <description>Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo and psychosocial intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Status</title>
          <description>vital status as measured by death</description>
          <units>number of participants who died</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Electrolytes</title>
        <description>Percent abnormal at 6 weeks as assessed by local lab</description>
        <time_frame>6 weeks</time_frame>
        <population>One patient in the active group completed all visit 6 assessments except for the blood collection for the electrolyte sample. This patient refused this procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Methylphenidate</title>
            <description>Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), and psychosocial intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo and psychosocial intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Electrolytes</title>
          <description>Percent abnormal at 6 weeks as assessed by local lab</description>
          <population>One patient in the active group completed all visit 6 assessments except for the blood collection for the electrolyte sample. This patient refused this procedure.</population>
          <units>percentage of abnormal electrolyte value</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.81"/>
                    <measurement group_id="O2" value="10.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.41"/>
                    <measurement group_id="O2" value="10.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.41"/>
                    <measurement group_id="O2" value="10.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Electrocardiogram (ECG)</title>
        <description>Abnormal electrocardiogram results at 6 weeks</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Methylphenidate</title>
            <description>Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo and psychosocial intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Electrocardiogram (ECG)</title>
          <description>Abnormal electrocardiogram results at 6 weeks</description>
          <units>participants with abnormal ECG</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>treatment period (i.e., 6 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Methylphenidate</title>
          <description>Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>matching placebo and psychosocial intervention</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>drop in hemoglobin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurry vision or eyesight changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>weight loss</sub_title>
                <description>greater than 2% at week 6</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Depressed appetite</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>agitation</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tics (motor or verbal)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggressive behavior or hostility</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash, redness, or inflammation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Distractibility</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Impaired learning</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Blood pressure changes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne Casper, MA</name_or_title>
      <organization>Johns Hopkins</organization>
      <phone>410-955-8183</phone>
      <email>ashankli@jhsph.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

